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Sir,
With great interest, we read the publication ‘Surveillance of
women at high risk for hereditary ovarian cancer is inefficient’
published by Oei et al (2006) in your journal. The authors evaluated
the efficacy of 10-year gynaecological surveillance in 512 women at
risk for hereditary ovarian cancer in a tertiary referral centre. This
gynaecological surveillance included annual pelvic examination,
transvaginal ultrasound (TVU) and serum CA125 measurements.
In case of abnormal findings in at least one of the surveillance tests,
revision of the abnormal test after 3–6 months was advised. A total
of 1621 surveillance tests were performed. In 317 contacts (21%),
TVU showed abnormal findings. Of these, 295 (93%) were not
present during repeat TVU after 3–6 months. Because only two
cases of ovarian cancer were diagnosed during this annual
surveillance, it can be calculated that the highest estimate for a
positive predictive value of an abnormal TVU is 0.6%.
This figure of 21% abnormal findings on TVU needs further
discussion than the authors give in this paper. The criteria in the
method section of this study, according to which TVU was
considered as abnormal were: multiple cysts, cysts with thick
septa, papillary projection, irregular patterns or a variety in
sonolucency. In the discussion section, the authors explain their
high percentage of false-positive findings on TVU with the
observation that the majority of their patients were premenopausal
and that a variety of benign conditions (e.g. follicle cysts) have
contributed to the high incidence of normalising abnormalities. It
is remarkable that the list of criteria used in this study according to
which TVU was considered abnormal, does not include the
presence and/or size of monolocular cysts. According to the
Sassone criteria, only cysts of more than 6cm need further
investigation in premenopausal women (Sassone et al, 1991). A
second point of attention is that it is not mentioned whether the
authors found any adverse effects in this group of patients who had
to wait for 3–6 months before they could be reassured by a repeat
TVU. It is known from literature that ovarian cancer screening in
high-risk women can have a great impact on the anxiety score,
especially of premenopausal women (Hensley et al, 2003).
We agree with the authors that surveillance is highly ineffective
to detect early ovarian (tubal) cancer in high-risk women. It can be
questioned whether their suggestion to conduct a study with a
larger group of BRCA mutation carriers with a longer follow-up is
in line with this conclusion. However, if they need more definitive
conclusions, as they suggested, they should define their TVU
criteria more precisely in order to avoid this high percentage of
false-positive TVU findings and the high loss of quality of life in
women with a false-positive TVU finding.
REFERENCES
Hensley ML, Robson ME, Kauff ND, Korytowsky B, Castiel M, Ostroff J,
Hurley K, Hann LE, Colon J, Spriggs D (2003) Pre- and postmenopausal
high-risk women undergoing screening for ovarian cancer: anxiety, risk
perceptions, and quality of life. Gynecol Oncol 89(3): 440–446
Oei AL, Massuger LF, Bulten J, Ligtenberg MJ, Hoogerbrugge N, de Hullu
JA (2006) Surveillance of women at high risk for hereditary ovarian
cancer is inefficient. Br J Cancer 94: 814–819
Sassone AM, Timor-Tritsch IE, Artner A, Westhoff C, Warren WB (1991)
Transvaginal sonographic characterization of ovarian disease: evaluation
of a new scoring system to predict ovarian malignancy. Obstet Gynecol
78(1): 70–76
*Correspondence: Dr MJE Mourits; E-mail: m.j.e.mourits@og.umcg.nl
British Journal of Cancer (2006) 95, 1125
& 2006 Cancer Research UK All rights reserved 0007– 0920/06 $30.00
www.bjcancer.com